Translational Hematology

Tipologia: Ematologia

Principal Investigator: Arcaini

In lymphoid neoplasms the aim it to investigate the mechanisms underlying rare B-cell lymphoproliferative disorders (lymphomas associated with HCV infection or with autoimmune diseases, unclussified) through the precision medicine methodology; a machine learning approach will also been applied combing clinical, histological and molecular data to ameliorate diagnostic assessment.

Investigations of drivers of lymphoma and CLL development may help us better identify clinical and prognostically features of and could provide suggestions to define a better nosological classification and to set up a personalized management of this hard-to-treat setting of patients.

Other field of investigation is the role of endothelial dysfunction in the setting of allogeneic transplant and CAR-T.

In acute leukemia our projects range over different topics, from pharmacokinetics to molecular biology, to immunology. Specifically, in collaboration with othercenters, we have a running project on the pharmacokinetics of the BCL2 inhibitor Venetoclax in combination with azoles in treating the AML of the elderly. Moreover, we are conducting a multicenter study on the molecular pathogenesis of rare type of acute leukemia by using a next generation sequencing approach.Eventually, we are exploring the role of the bone marrow microenvironment in the mechanism of resistance to chemiotherapy, by studying the bone marrow mesenchimal cells in NPM1 mutated AML.

Merli M., Rattotti S., Spina M., Re F., Motta M., Piazza F., Orsucci L., Ferreri A.J.M., Perbellini O., Dodero A., Vallisa D., Pulsoni A., Santoro A., Sacchi P., Zuccaro V., Chimienti E., Russo F., Visco C., Zignego A.L., Marcheselli L., Passamonti F., Luminari S., Paulli M., Bruno R., Arcaini L., Fondazione Italiana Linfomi. Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. Journal of Clinical Oncology, 2022;
Mangiacavalli S., Cartia C.S., Galli M., Pezzatti S., Belotti A., Fazio F., Mina R., Marcatti M., Cafro A., Zambello R., Paris L., Barilà G., Olivares C., Pompa A., Mazza R., Farina F., Soldarini M., Benvenuti P., Pagani G., Palumbo M., Masoni V., Ferretti V.V., Klersy C., Arcaini L., Petrucci M.T. Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis. Haematologica, 2022;
Gallamini A., Picardi M., Filonenko K.,Gotti M., Céspedes J.N, Javier N., Rossi A., Domingo-Domènech E., Giza A., Sorasio R., Trentin L, Oteiro M.B., Paszkiewicz-Kozik E., Sanz R.G., Patti C., Chauvie S., Bergesio F., Guerra L., Rambaldi A., Balari A.S., Zaucha J.M. T021: Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial. Hemapshere, 2022;
Varettoni M., Orlandi E., Zibellini S., Rossi M., Gentile M., Flospergher E., Ferretti V.V., Rizzo E., Della Porta M.G., Rattotti S., Cavalloni C., Bergamini F., Cristinelli C., Fabbri N., Gallì A., Arcaini L. Prognostic impact of somatic mutations on time to first treatment: Results of targeted next-generation sequencing in 211 patients with early stage chronic lymphocytic leukemia. American Journal of Hematology, 2021.